Israeli ophthalmology startup, EyeYon Medical, has received a CE Mark for its flagship product EndoArt, the world’s first synthetic corneal implant designed to counteract corneal edema.
Edema is the excess build-up of fluids in the cornea caused by damaged endothelial cells, which usually regulate hydration levels in the eye. It can result in irreversible scarring, pain and even blindness....
Ophthalmic startup EyeYon Medical announced today the completion of a $25 million in a Series C funding.
The round was led by CR-CP Life Science Fund, which invests in life science companies that develop drugs, cell therapies, medical devices, and smart healthcare technology.
Other participants in the round include Global Health Sciences (GHS) Fund (Quark Venture LP and GF Securities), BPC and...
